A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy/Potency of a Single Dose of Xisomab 3G3, Administered at the Beginning of a Regular Hemodialysis Procedure, in Patients With End-Stage Renal Disease on Chronic Hemodialysis
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Xisomab 3G3 (Primary)
- Indications Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aronora
- 16 Nov 2019 Status changed from active, no longer recruiting to completed.
- 25 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.